Edition:
India

Arvinas Inc (ARVN.OQ)

ARVN.OQ on NASDAQ Stock Exchange Global Select Market

24.49USD
20 Sep 2019
Change (% chg)

-- (--)
Prev Close
$24.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
68,995
52-wk High
$28.21
52-wk Low
$10.22

Latest Key Developments (Source: Significant Developments)

Arvinas Says Under Terms Of Bayer Agreement, Co Will Receive Upfront Payment Of $17.5 Mln Within 30 Days Of The Effective Date
Tuesday, 4 Jun 2019 

June 4 (Reuters) - Arvinas Inc ::ARVINAS INC - UNDER TERMS OF BAYER COLLABORATION AGREEMENT, CO WILL RECEIVE UPFRONT PAYMENT OF $17.5 MILLION WITHIN 30 DAYS OF THE EFFECTIVE DATE..ARVINAS INC - ALSO ENTITLED TO RECEIVE UP TO AN ADDITIONAL $12.0 MILLION IN RESEARCH FUNDING PAYMENTS.ARVINAS-ELIGIBLE TO RECEIVE, ON NET SALES OF PROTAC TARGETED PROTEIN DEGRADER-RELATED PRODUCTS, MID-SINGLE DIGIT TO LOW-DOUBLE DIGIT TIERED ROYALTIES.ARVINAS-ALSO ELIGIBLE TO RECEIVE UP TO $197.5 MILLION IN DEVELOPMENT MILESTONES AND UP TO $490.0 MILLION IN SALES-BASED MILESTONES FOR ALL DESIGNATED TARGETS..  Full Article

Bayer And Arvinas To Develop Novel Proteolysis-Targeting Chimera Candidates For Humans And Plants
Tuesday, 4 Jun 2019 

June 4 (Reuters) - BAYER AG ::BAYER AND ARVINAS, INC. TO DEVELOP NOVEL PROTEOLYSIS-TARGETING CHIMERA CANDIDATES FOR HUMANS AND PLANTS.AGREEMENT WORTH MORE THAN USD 110 MILLION.BAYER AND ARVINAS TO LAUNCH JOINT VENTURE TO DEVELOP TARGETED PROTEIN DEGRADERS FOR AGRICULTURE APPLICATIONS.COLLABORATION AGREEMENT AND EQUITY INVESTMENT BY BAYER TO DEVELOP NEXT-GENERATION MEDICINES FOR PATIENTS WITH CARDIOVASCULAR, ONCOLOGICAL AND GYNECOLOGICAL DISEASES.UNDER TERMS OF AGREEMENT, ARVINAS WILL RECEIVE AN UPFRONT PAYMENT AND PHARMACEUTICAL R&D SUPPORT OVER NEXT FOUR YEARS, AS WELL AS A DIRECT EQUITY INVESTMENT.THESE INVESTMENTS COMBINED WILL EXCEED USD 60 MLN.ARVINAS MIGHT ALSO BE ELIGIBLE TO RECEIVE PRE-DEFINED DEVELOPMENT MILESTONES OF OVER USD 685 MLN AND COMMERCIAL ROYALTIES.  Full Article

Bayer And Arvinas To Collaborate On Human Protac Therapies And Launch A Separate Joint Venture To Develop Agricultural Protac Applications
Tuesday, 4 Jun 2019 

June 4 (Reuters) - Arvinas Inc ::BAYER AND ARVINAS TO COLLABORATE ON HUMAN PROTAC® THERAPIES AND LAUNCH A SEPARATE JOINT VENTURE TO DEVELOP AGRICULTURAL PROTAC® APPLICATIONS.ARVINAS INC - BAYER AND ARVINAS TO LAUNCH A JOINT VENTURE TO DEVELOP TARGETED PROTEIN DEGRADERS FOR AGRICULTURAL APPLICATIONS.ARVINAS INC - $110M+ LIFE SCIENCES DEAL TO DEVELOP NOVEL PROTAC® CANDIDATES.ARVINAS INC - OVERALL SERIES OF ARRANGEMENTS INCLUDES OVER $110 MILLION IN UPFRONT CASH AND COMMITTED FUNDING FOR HUMAN DISEASE COLLABORATION.ARVINAS INC - CLOSING OF THE MULTI-FACETED DEAL WITH BAYER, OTHERS WILL LEAD TO UPDATED FINANCIAL GUIDANCE FOR ARVINAS.ARVINAS INC - BAYER WILL OWN RIGHTS TO NOVEL LEAD STRUCTURES GENERATED IN COLLABORATION.ARVINAS - ALSO ELIGIBLE TO GET DEVELOPMENT MILESTONES OF OVER $685 MILLION & COMMERCIAL ROYALTIES RANGING FROM MID-SINGLE DIGITS TO LOW DOUBLE-DIGITS.ARVINAS INC - ARVINAS WILL RECEIVE AN UPFRONT PAYMENT AND COMMITTED RESEARCH AND DEVELOPMENT FUNDING, AS WELL AS A DIRECT EQUITY INVESTMENT IN ARVINAS.ARVINAS INC - BAYER AND ARVINAS WILL EQUALLY SHARE GOVERNANCE AND EQUITY OWNERSHIP OF JV.ARVINAS - THE JV WILL BE SUPPORTED BY IP & OVER $55 MILLION IN COMMITTED FUNDING FROM BAYER, AND BY TECHNOLOGY AND INTELLECTUAL PROPERTY FROM ARVINAS.  Full Article